晶泰科技：就AI赋能双特异性抗体与礼来达成3.45亿美元平台战略合作

Core Insights - Jingtai Technology announced a strategic multi-target collaboration and platform licensing agreement with Eli Lilly, with a total value of up to $345 million [1] - The agreement includes several tens of millions of dollars in upfront payments and milestone payments [1] - Eli Lilly will leverage Ailux's proprietary platform to accelerate the discovery and development of bispecific antibodies across multiple therapeutic areas [1] - The AI antibody development platform will also be utilized to enhance Eli Lilly's internal pipeline research [1]